Organogenesis Holdings Inc

Organogenesis maintains a conservative capital structure with a debt-to-equity ratio of 0.05, indicating minimal leverage. The company's liquidity position is assessed as medium, with a current ratio of 3.62, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow of $24.47 million supports operational flexibility, though operating cash flow is negative at -$10.31 million, indicating reliance on non-operational cash inflows. Profitability metrics show a return on equity of 8.53% and a return on assets of 6.19%, both below the industry median for Biotechnology & Medical Research firms. The company's net income of $37.03 million on $564.17 million in revenue yields a net margin of 6.57%, which is in line with the sector average. Gross profit of $426.65 million on $564.17 million in revenue reflects a gross margin of 75.63%, a strong indicator of cost control in production. The company's revenue is concentrated in the United States, with no material geographic diversification disclosed. Segment-wise, ACell and Cytori Therapeutics are the primary contributors, though revenue by segment is not explicitly broken out in the latest financials. This lack of segmental transparency may obscure growth opportunities or risks within specific product lines. Organogenesis reported revenue of $564.17 million in the latest period, with no year-over-year growth data provided. Analysts have assigned a mean price target of $8.00, significantly higher than the current market price of $2.59, suggesting strong upside potential. However, the absence of forward-looking guidance or revenue growth projections limits visibility into the company's trajectory. The company faces moderate liquidity risk due to negative net cash after subtracting total debt, and its dilution risk is assessed as low. No recent equity issuance or dilutive events are disclosed, and the number of shares outstanding has remained stable. The absence of a significant capital raise or share buyback program suggests a neutral stance on capital structure adjustments. Recent filings and transcripts do not disclose material events or strategic shifts. The company's focus remains on its core regenerative medicine and wound care products, with no new therapeutic areas or partnerships announced in the latest disclosures.